HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dawn Waterhouse Selected Research

QLT 0267

5/2011Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267.
1/2009QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Dawn Waterhouse Research Topics

Disease

12Neoplasms (Cancer)
02/2015 - 10/2004
5Breast Neoplasms (Breast Cancer)
05/2011 - 11/2006
2Colorectal Neoplasms (Colorectal Cancer)
02/2015 - 10/2004
2Carcinoma (Carcinomatosis)
02/2013 - 07/2011
2Ovarian Neoplasms (Ovarian Cancer)
02/2013 - 06/2010
2Neoplasm Metastasis (Metastasis)
05/2011 - 10/2004
1Dysbiosis
05/2020
1Cross Infection (Nosocomial Infection)
11/2019
1Colonic Neoplasms (Colon Cancer)
02/2015
1Ascites
05/2011
1Hypoxia (Hypoxemia)
05/2011
1Acidosis
05/2011
1Disease Progression
05/2011
1Vascular Tissue Neoplasms
04/2011
1Glioblastoma (Glioblastoma Multiforme)
04/2011
1Adenocarcinoma
03/2008
1Weight Loss (Weight Reduction)
11/2006
1Melanoma (Melanoma, Malignant)
07/2002

Drug/Important Bio-Agent (IBA)

9Pharmaceutical PreparationsIBA
11/2019 - 10/2004
6Irinotecan (Camptosar)FDA LinkGeneric
02/2015 - 10/2004
3LipidsIBA
02/2015 - 07/2002
3Liposomes (Liposome)IBA
02/2013 - 11/2006
3Docetaxel (Taxotere)FDA Link
05/2011 - 01/2009
2LactonesIBA
02/2015 - 02/2008
2bisbenzimide ethoxide trihydrochloride (Hoechst 33342)IBA
02/2015 - 04/2011
2Proteins (Proteins, Gene)FDA Link
07/2011 - 05/2011
2integrin-linked kinaseIBA
05/2011 - 01/2009
2QLT 0267IBA
05/2011 - 01/2009
1Fluorouracil (Carac)FDA LinkGeneric
02/2015
1Topotecan (Hycamtin)FDA LinkGeneric
02/2013
1liposomal doxorubicin (Doxil)FDA Link
02/2013
1PlatinumIBA
02/2013
1AmyloseIBA
07/2011
1CarbohydratesIBA
07/2011
1Glucose (Dextrose)FDA LinkGeneric
07/2011
1Biomarkers (Surrogate Marker)IBA
05/2011
1LuciferasesIBA
05/2011
1Carbonic Anhydrase IXIBA
05/2011
1CaspasesIBA
05/2011
1Small Interfering RNA (siRNA)IBA
05/2011
1Doxorubicin (Adriamycin)FDA LinkGeneric
04/2011
1Vincristine (Oncovin)FDA LinkGeneric
04/2011
1ProdrugsIBA
06/2010
1Saline SolutionIBA
03/2009
1Actins (F Actin)IBA
01/2009
1Drug CombinationsIBA
01/2009
1human ERBB2 proteinIBA
01/2009
1Therapeutic UsesIBA
01/2009
1Cytostatic AgentsIBA
01/2009
1Calcimycin (A23187)IBA
03/2008
1MicellesIBA
11/2006
1EconazoleFDA LinkGeneric
11/2006
1Antineoplastic Agents (Antineoplastics)IBA
11/2006
1Blood Proteins (Serum Proteins)IBA
07/2002
1OligodeoxyribonucleotidesIBA
07/2002
1Lipoproteins (Lipoprotein)IBA
07/2002
1oblimersen (G3139)IBA
07/2002

Therapy/Procedure

3Drug Therapy (Chemotherapy)
04/2011 - 01/2009
1Precision Medicine
05/2020
1Caloric Restriction
07/2011
1High-Protein Low-Carbohydrate Diet (Atkins Diet)
07/2011
1Therapeutics
05/2011
1Aftercare (After-Treatment)
10/2004